This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): DR-1031, levonorgestrel/ethinyl estradiol with ethinyl estradiol, DR-103, 91-day extended regimen oral contraceptive
Description: DR-103 is a combination oral contraceptive regimen consisting of levonorgestrel/ethinyl estradiol 0.15/0.02 mg for 42 days, then levonorgestrel/ethinyl estradiol 0.15/0.025 mg for 21 days, then levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days and finally, ethinyl estradiol 0.01 mg for 7 days.
Deal Structure: DR-103 was originally developed by Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals.
In July 2008, Teva Pharmaceutical and Barr Pharmaceuticals announced that they have signed a definitive agreement under which Teva will acquire Barr. The acquisition was completed in December 2008.
Additional information available to subscribers only: